We are analyzing https://link.springer.com/article/10.1007/s44192-024-00066-5.

Title:
Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study | Discover Mental Health
Description:
Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF) metabolome correlate with scores on questionnaires and response to medication. We performed a retrospective pilot study to evaluate phenotypic and metabolomic variability in patients with treatment-resistant depression using multivariate data compression algorithms. Twenty-nine patients with treatment-resistant depression provided fasting CSF samples. Over 300 metabolites were analyzed in these samples with liquid chromatography-mass spectrometry. Chart review provided basic demographic information, clinical status with self-reported questionnaires, and response to medication. Of the 300 metabolites analyzed, 151 were present in all CSF samples and used in the analyses. Hypothesis-free multivariate analysis compressed the resultant data set into two dimensions using Principal Component (PC) analysis, accounting for ~ 32% of the variance. PC1 accounted for 16.9% of the variance and strongly correlated with age in one direction and 5-methyltetrahydrofolate, homocarnosine, and depression and anxiety scores in the opposite direction. PC2 accounted for 15.4% of the variance, with one end strongly correlated with autism scores, male gender, and cognitive fatigue scores, and the other end with bipolar diagnosis, lithium use, and ethylmalonate disturbance. This small pilot study suggests that complex treatment-resistant depression can be mapped onto a 2-dimensional pathophysiological domain. The results may have implications for treatment selection for depression subtypes.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,170,236 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pubmed, depression, article, ketamine, patients, metabolites, google, scholar, analysis, data, csf, response, clinical, metabolomic, study, central, disorder, treatmentresistant, patient, mitochondrial, cas, bipolar, figure, scores, treatment, health, lithium, chronic, supplemental, item, mthf, samples, activity, pca, metabolome, autism, psychiatry, high, correlation, cerebrospinal, fluid, medication, analyzed, variance, age, anxiety, ksp, rapamycin, cluster, components,

Topics {✒️}

microglial erk-nrbp1-creb-bdnf signaling liquid chromatography-mass spectrometry asperger syndrome/high-functioning autism treatment-resistant post-traumatic epilepsy branched-chain amino acids numerous fda-approved drugs genome-wide association study article download pdf l-methylfolate fda approval alpha-ketoglutarate substrate-derived cerebrospinal fluid metabolomes a1 pro-inflammatory astrocyte reliable fuel-switching markers hypoxia-induced insulin resistance blood–brain barrier kinetics google scholar mood disorders-remission state baseline tor1/tor2 activity central clusters differently antidepressant-dose ketamine administration complex treatment-resistant depression treatment-resistant depression subtypes patient z-score distribution lithium treatment-moderate dose dsm-5 mental disorders human research protections article berner treatment-resistant bipolar depression spitzer rl full access privacy choices/manage cookies jon berner individually widely divergent assess functional disability gamma-aminobutyric acid folinic acid supplementation coupled inflammatory phenotype random forest analysis increased phenotypic conversion cerebrospinal fluid metabolome mitochondrial dysfunction hypothesis blood gene expression gene-expression differences metabolic dimension reduction decreased mitochondrial mass multivariate data acquisition random forest modelling 6-item karolinska scales medical chart review avoid statistical issues

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
         description:Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF) metabolome correlate with scores on questionnaires and response to medication. We performed a retrospective pilot study to evaluate phenotypic and metabolomic variability in patients with treatment-resistant depression using multivariate data compression algorithms. Twenty-nine patients with treatment-resistant depression provided fasting CSF samples. Over 300 metabolites were analyzed in these samples with liquid chromatography-mass spectrometry. Chart review provided basic demographic information, clinical status with self-reported questionnaires, and response to medication. Of the 300 metabolites analyzed, 151 were present in all CSF samples and used in the analyses. Hypothesis-free multivariate analysis compressed the resultant data set into two dimensions using Principal Component (PC) analysis, accounting for ~ 32% of the variance. PC1 accounted for 16.9% of the variance and strongly correlated with age in one direction and 5-methyltetrahydrofolate, homocarnosine, and depression and anxiety scores in the opposite direction. PC2 accounted for 15.4% of the variance, with one end strongly correlated with autism scores, male gender, and cognitive fatigue scores, and the other end with bipolar diagnosis, lithium use, and ethylmalonate disturbance. This small pilot study suggests that complex treatment-resistant depression can be mapped onto a 2-dimensional pathophysiological domain. The results may have implications for treatment selection for depression subtypes.
         datePublished:2024-04-17T00:00:00Z
         dateModified:2024-04-17T00:00:00Z
         pageStart:1
         pageEnd:12
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s44192-024-00066-5
         keywords:
            Psychiatry
            Psychotherapy
            Clinical Psychology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs44192-024-00066-5/MediaObjects/44192_2024_66_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs44192-024-00066-5/MediaObjects/44192_2024_66_Fig2_HTML.png
         isPartOf:
            name:Discover Mental Health
            issn:
               2731-4383
            volumeNumber:4
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jon Berner
               url:http://orcid.org/0000-0003-3117-6482
               affiliation:
                     name:Woodinville Psychiatric Associates
                     address:
                        name:Woodinville Psychiatric Associates, Woodinville, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Animesh Acharjee
               affiliation:
                     name:University of Birmingham
                     address:
                        name:Institute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, UK
                        type:PostalAddress
                     type:Organization
                     name:University Hospitals Birmingham NHS Foundation Trust
                     address:
                        name:Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
                        type:PostalAddress
                     type:Organization
                     name:MRC Health Data Research UK (HDR UK)
                     address:
                        name:MRC Health Data Research UK (HDR UK), London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
      description:Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF) metabolome correlate with scores on questionnaires and response to medication. We performed a retrospective pilot study to evaluate phenotypic and metabolomic variability in patients with treatment-resistant depression using multivariate data compression algorithms. Twenty-nine patients with treatment-resistant depression provided fasting CSF samples. Over 300 metabolites were analyzed in these samples with liquid chromatography-mass spectrometry. Chart review provided basic demographic information, clinical status with self-reported questionnaires, and response to medication. Of the 300 metabolites analyzed, 151 were present in all CSF samples and used in the analyses. Hypothesis-free multivariate analysis compressed the resultant data set into two dimensions using Principal Component (PC) analysis, accounting for ~ 32% of the variance. PC1 accounted for 16.9% of the variance and strongly correlated with age in one direction and 5-methyltetrahydrofolate, homocarnosine, and depression and anxiety scores in the opposite direction. PC2 accounted for 15.4% of the variance, with one end strongly correlated with autism scores, male gender, and cognitive fatigue scores, and the other end with bipolar diagnosis, lithium use, and ethylmalonate disturbance. This small pilot study suggests that complex treatment-resistant depression can be mapped onto a 2-dimensional pathophysiological domain. The results may have implications for treatment selection for depression subtypes.
      datePublished:2024-04-17T00:00:00Z
      dateModified:2024-04-17T00:00:00Z
      pageStart:1
      pageEnd:12
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s44192-024-00066-5
      keywords:
         Psychiatry
         Psychotherapy
         Clinical Psychology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs44192-024-00066-5/MediaObjects/44192_2024_66_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs44192-024-00066-5/MediaObjects/44192_2024_66_Fig2_HTML.png
      isPartOf:
         name:Discover Mental Health
         issn:
            2731-4383
         volumeNumber:4
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jon Berner
            url:http://orcid.org/0000-0003-3117-6482
            affiliation:
                  name:Woodinville Psychiatric Associates
                  address:
                     name:Woodinville Psychiatric Associates, Woodinville, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Animesh Acharjee
            affiliation:
                  name:University of Birmingham
                  address:
                     name:Institute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, UK
                     type:PostalAddress
                  type:Organization
                  name:University Hospitals Birmingham NHS Foundation Trust
                  address:
                     name:Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
                     type:PostalAddress
                  type:Organization
                  name:MRC Health Data Research UK (HDR UK)
                  address:
                     name:MRC Health Data Research UK (HDR UK), London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Discover Mental Health
      issn:
         2731-4383
      volumeNumber:4
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Woodinville Psychiatric Associates
      address:
         name:Woodinville Psychiatric Associates, Woodinville, USA
         type:PostalAddress
      name:University of Birmingham
      address:
         name:Institute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, UK
         type:PostalAddress
      name:University Hospitals Birmingham NHS Foundation Trust
      address:
         name:Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
         type:PostalAddress
      name:MRC Health Data Research UK (HDR UK)
      address:
         name:MRC Health Data Research UK (HDR UK), London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jon Berner
      url:http://orcid.org/0000-0003-3117-6482
      affiliation:
            name:Woodinville Psychiatric Associates
            address:
               name:Woodinville Psychiatric Associates, Woodinville, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Animesh Acharjee
      affiliation:
            name:University of Birmingham
            address:
               name:Institute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, UK
               type:PostalAddress
            type:Organization
            name:University Hospitals Birmingham NHS Foundation Trust
            address:
               name:Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
               type:PostalAddress
            type:Organization
            name:MRC Health Data Research UK (HDR UK)
            address:
               name:MRC Health Data Research UK (HDR UK), London, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Woodinville Psychiatric Associates, Woodinville, USA
      name:Institute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, UK
      name:Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
      name:MRC Health Data Research UK (HDR UK), London, UK

External Links {🔗}(165)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.99s.

LINK . SPRINGER . COM {}